US EditionGLP-1 Agents Linked to Lower Cancer Risk Among Adults with Obesity
A study of 86,632 adults with obesity found GLP-1 receptor agonists reduced overall cancer risk by 17%, notably lowering endometrial, ovarian, and meningioma cancer incidence.
8 Articles
8 Articles
GLP-1 agents linked to lower cancer risk among adults with obesity
GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant reduction in risk for overall cancer. The protective effect appeared particularly strong for endometrial cancer, ovarian cancer and meningioma.
The use of LPG1 agonists is associated with a reduction in the overall risk of cancer. This is the conclusion of a study published on Wednesday by the scientific journal Jama Oncology. The study, conducted with data from more than 86,000 obese or overweight adults for 10 years, compared the clinical histories of patients who had been taking these anti-obesity drugs (known by their commercial names as Ozempic or Wegovy) with patients who had not …
In particular, the use of this family of medications was associated with a reduction in the risk of cancer of endometrial, ovary and meningioma La entrada Antiobesity drugs are associated with a lower risk of cancer in overweight people was first published in La Voz de Michoacán.
Scienmag: Latest Science and Health News
BIOENGINEER.ORGExamining the Link Between GLP-1 Receptor Agonists and Cancer Risk in
In a groundbreaking retrospective cohort study published in the highly respected journal JAMA Oncology, researchers have unveiled compelling evidence that glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of medications primarily prescribed to manage obesity and type 2 diabetes, may harbor cancer-related benefits beyond their metabolic effects. The investigation levels a nuanced understanding of how these peptides could influence can…
Good News on GLP-1s and Cancer Risk, With One Exception
(MedPage Today) — Patients taking GLP-1 agonists for weight loss had a small but significantly lower risk of developing cancer, a large retrospective cohort study showed. With follow-up ranging from 1 to 11 years, use of GLP-1 agonists, such… Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/117100 Author : Publish date : 2025-08-21 15:45:00 Copyright for syndicated content belongs […] The post Good News on GLP-1s and Ca…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
